February 2026 in “ImmunoTargets and Therapy” Tumor immunotherapy can cause hair loss by disrupting hair follicle immunity.
22 citations
,
January 2012 in “Mediators of inflammation” Nonantibiotic macrolides show promise for treating various inflammatory skin conditions.
24 citations
,
March 2018 in “Experimental Dermatology” Treg dysfunction is linked to various autoimmune skin diseases, and understanding Treg properties is key for new treatments.
86 citations
,
June 2018 in “Cochrane library” Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
November 2025 in “Journal of Investigative Dermatology” Certain immune cells in atopic dermatitis skin could be targeted for treatment.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
9 citations
,
April 2024 in “The Oncologist” Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
5 citations
,
July 2003 in “Annals of the Rheumatic Diseases” An antibiotic called co-trimoxazole can effectively treat autoimmune diseases.
January 2026 in “Immune Network” Regulatory T cells adapt to different environments to control inflammation and support tissue repair.
11 citations
,
May 2010 in “Journal of the South African Veterinary Association” Mycophenolate mofetil helped reduce steroid use in treating a dog's autoimmune skin disease.
14 citations
,
April 2017 in “American Journal of Transplantation” Skin problems from transplant drugs are common and need careful management in organ transplant patients.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
3 citations
,
January 2011 in “American Journal of Hematology” Immunochemotherapy successfully treated neutropenia in a patient with Waldenström's macroglobulinemia.
6 citations
,
August 2013 in “Joint Bone Spine” Tocilizumab treatment was associated with significant hair regrowth in one patient and temporary hair loss followed by regrowth in another.
November 2025 in “Journal of Investigative Dermatology” Dithranol reduces inflammation in alopecia areata by lowering certain immune responses.
5 citations
,
July 2019 in “Investigational new drugs” TLR7-based compounds may help manage chemotherapy-induced hair loss.
3 citations
,
March 2016 in “Practical radiation oncology” Total skin electron therapy is an effective treatment for mycosis fungoides, balancing effectiveness and side effects.
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.
44 citations
,
November 2022 in “Frontiers in Immunology” TLR-targeted therapies show promise in cancer treatment by helping destroy tumors.
1 citations
,
November 2016 in “Journal of dermatological treatment” Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
3 citations
,
February 2020 in “The Egyptian Rheumatologist” Recognizing LET and AITD can help diagnose SLE early for better treatment.
9 citations
,
February 2011 in “Biologics: Targets & Therapy” Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
26 citations
,
February 2021 in “FEBS Journal” Targeting regulatory T cells may help treat age-related diseases.
1 citations
,
January 2024 in “Pharmaceuticals” A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.
TLR3 signaling enhances the immunosuppressive properties of human periodontal ligament stem cells.
January 2025 in “Journal of Crohn s and Colitis” Tofacitinib is effective and safe for elderly patients with ulcerative colitis.
August 2019 in “Journal of Invertebrate Pathology” Thymosin beta 4 protects cells from damage by blocking a harmful microRNA and boosting a protective gene.